Source study found

Story checked

Finnish study finds poor oral health increases jawbone necrosis risks in breast cancer patients (opens in a new tab)

news-medical.net · 2026-10-14

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

3 supported
2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Finnish study finds poor oral health increases jawbone necrosis risks in breast cancer patients

news-medical.net · 2026-10-14

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

3 supported
2 not covered

Open claim evidence

The source study

Incidence and associated factors of medication-related osteonecrosis of the jaw in breast cancer patients with bone metastases: a nationwide registry study in Finland

Clinical Oral Investigations · 2026Open access

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe study found associations between dental procedures related to oral infections and osteonecrosis of the jaw, with tooth extraction and root canal treatment in particular associated with a higher risk of the condition.View evidenceHide evidence

Why this verdict

The abstract-level profile supports a general association between infection-related invasive dental procedures and MRONJ, but it does not specify tooth extraction or root canal treatment. Those procedure-specific details cannot be verified from the supplied abstract-depth profile.

Study evidence

Denosumab monotherapy was associated with substantially increased MRONJ risk compared with bisphosphonate therapy.substantially increased risk (numeric estimate not reported in abstract)

Claim 2 of 5Not coveredThe researchers said the findings do not establish that dental procedures cause osteonecrosis of the jaw and do not warrant changing or discontinuing anti-resorptive treatment.View evidenceHide evidence

Why this verdict

The observational design supports caution against causal interpretation in general, but the supplied abstract-depth profile does not verify that the researchers specifically said the findings do not warrant changing or discontinuing anti-resorptive treatment.

Study evidence

Denosumab monotherapy was associated with substantially increased MRONJ risk compared with bisphosphonate therapy.substantially increased risk (numeric estimate not reported in abstract)

Claim 3 of 5SupportedIn a Finnish registry study, osteonecrosis of the jaw was diagnosed in 12.6% of patients treated with denosumab during long-term follow-up.View evidenceHide evidence

As stated12.6%

Why this verdict

The abstract-level profile reports that MRONJ incidence was 12.6% among denosumab users in this nationwide Finnish retrospective registry cohort followed through 2020. The story’s wording is descriptive rather than causal.

Study evidence

Among bisphosphonate users, the incidence of MRONJ was reported as ranging from 0% to 2.2%.0%–2.2%

Study evidence

Denosumab monotherapy was associated with substantially increased MRONJ risk compared with bisphosphonate therapy.substantially increased risk (numeric estimate not reported in abstract)

Claim 4 of 5SupportedAmong patients who had initially received bisphosphonates before switching to denosumab, osteonecrosis of the jaw was diagnosed in 15.3% during follow-up, and the condition was diagnosed in a small proportion of patients treated with bisphosphonates alone.View evidenceHide evidence

As stated15.3%

Why this verdict

The profile reports 15.3% MRONJ incidence among patients receiving sequential bisphosphonate→denosumab therapy and 0%–2.2% among bisphosphonate users, which supports the statement that bisphosphonate-only patients had a small proportion diagnosed.

Study evidence

Among bisphosphonate users, the incidence of MRONJ was reported as ranging from 0% to 2.2%.0%–2.2%

Study evidence

Denosumab monotherapy was associated with substantially increased MRONJ risk compared with bisphosphonate therapy.substantially increased risk (numeric estimate not reported in abstract)

Claim 5 of 5SupportedThe study included 652 breast cancer patients with bone metastases who received anti-resorptive treatment between 2013 and 2015 and were followed until the end of 2020.View evidenceHide evidence

As stated652

Why this verdict

The profile states that the cohort included 652 adult breast cancer patients with bone metastases prescribed antiresorptive therapy between 2013 and 2015 and followed through 2020.

Study evidence

Among bisphosphonate users, the incidence of MRONJ was reported as ranging from 0% to 2.2%.0%–2.2%

Study evidence

Denosumab monotherapy was associated with substantially increased MRONJ risk compared with bisphosphonate therapy.substantially increased risk (numeric estimate not reported in abstract)

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

MRONJ was ascertained using the ICD-10 M87.1 diagnosis code in administrative registers, and the abstract-depth profile does not report validation or adjudication of cases.
The story says MRONJ was diagnosed but does not mention reliance on registry diagnosis coding or the lack of abstract-level validation/adjudication information.
From retrospective cohort; Retrospective nationwide registry cohort
The abstract-depth profile does not provide numerical effect estimates, confidence intervals, p-values, or full model specifications for the association analyses.
The story reports qualitative risk associations but does not note that the supplied abstract-level evidence lacks detailed adjusted estimates and uncertainty measures.
From Retrospective nationwide registry cohort

7 things the story did carry across

The study was a nationwide Finnish retrospective registry cohort of adult breast cancer patients with bone metastases prescribed antiresorptive therapy in 2013–2015 and followed through 2020.
The cohort size was 652 patients.
MRONJ incidence differed by antiresorptive exposure group: 12.6% among denosumab users, 15.3% among sequential bisphosphonate→denosumab users, and 0%–2.2% among bisphosphonate users.
Denosumab monotherapy and sequential bisphosphonate→denosumab therapy were associated with substantially increased MRONJ risk compared with bisphosphonate therapy.
Infection-related invasive dental procedures were reported as strongly associated with MRONJ.
The evidence is observational and retrospective, so residual confounding and limited control of unmeasured variables are material limitations.
Details on timing, definitions, and coding of dental procedures and oral diseases relative to MRONJ onset are not provided at abstract depth.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEstimate the incidence of medication-related osteonecrosis of the jaw (MRONJ) among Finnish adult breast cancer patients with bone metastases receiving antiresorptive therapy (2013–2015) with follow-up through 2020 using nationwide registers.retrospective cohortExpand

In plain English

Retrospective nationwide registry cohort of adult Finnish breast cancer patients with bone metastases prescribed antiresorptive therapy in 2013–2015 (n=652) followed through 2020 to estimate incidence of medication-related osteonecrosis of the jaw (MRONJ, ICD-10 M87.1) overall and by antiresorptive exposure (bisphosphonate, denosumab, sequential bisphosphonate→denosumab). Incidence differed by therapy type, with higher occurrence among denosumab users and among patients receiving sequential bisphosphonate then denosumab; infection-related invasive dental procedures were also strongly associated with MRONJ in this cohort.

Key findings

Among bisphosphonate users, the incidence of MRONJ was reported as ranging from 0% to 2.2%.0%–2.2%
Among denosumab users, the reported incidence of MRONJ was 12.6%.12.6%

2secondary dataIdentify factors associated with MRONJ risk in this population, including type of antiresorptive therapy (bisphosphonates vs denosumab vs sequential therapy) and dental/infection-related procedures and comedications/comorbidities.Retrospective nationwide registry cohortExpand

In plain English

Retrospective nationwide registry cohort (Finland) of 652 adult breast cancer patients with bone metastases prescribed antiresorptive therapy (2013–2015) and followed through 2020 evaluated MRONJ (ICD M87.1) incidence and associations with covariates (age, oral diseases, dental procedures, antiresorptive type, comorbidities, concomitant medications). Denosumab use and infection-related invasive dental procedures were reported as the strongest predictors of MRONJ; denosumab monotherapy and sequential bisphosphonate→denosumab therapy were associated with substantially increased MRONJ risk compared with bisphosphonate therapy. Reported MRONJ incidence by therapy: 0–2.2% for bisphosphonates, 12.6% for denosumab, and 15.3% for sequential bisphosphonate→denosumab therapy.

Key findings

Denosumab monotherapy was associated with substantially increased MRONJ risk compared with bisphosphonate therapy.substantially increased risk (numeric estimate not reported in abstract)
Sequential bisphosphonate followed by denosumab therapy was associated with substantially increased MRONJ risk compared with bisphosphonate therapy.substantially increased risk (numeric estimate not reported in abstract)

What this piece can’t prove

Retrospective observational design using registry data; potential for residual confounding and limited control of unmeasured variables.
Outcome defined by diagnostic code M87.1 in administrative registers; abstract does not report validation or adjudication of MRONJ cases.
Abstract does not provide numerical effect estimates (e.g., hazard ratios or odds ratios), confidence intervals, p-values, or full model specifications.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer